Your browser is no longer supported. Please, upgrade your browser.
Settings
HTBX Heat Biologics, Inc. daily Stock Chart
HTBX [NASD]
Heat Biologics, Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own6.04% Shs Outstand82.70M Perf Week-2.24%
Market Cap308.62M Forward P/E- EPS next Y-0.27 Insider Trans0.00% Shs Float75.53M Perf Month144.37%
Income-20.60M PEG- EPS next Q-0.10 Inst Own12.20% Short Float2.86% Perf Quarter298.54%
Sales3.20M P/S96.44 EPS this Y33.20% Inst Trans-0.01% Short Ratio0.07 Perf Half Y754.57%
Book/sh0.47 P/B4.64 EPS next Y0.00% ROA-69.90% Target Price- Perf Year235.38%
Cash/sh0.19 P/C11.69 EPS next 5Y- ROE-103.60% 52W Range0.19 - 4.30 Perf YTD358.95%
Dividend- P/FCF- EPS past 5Y49.50% ROI-151.80% 52W High-50.47% Beta0.76
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin- 52W Low992.31% ATR0.40
Employees36 Current Ratio3.90 Sales Q/Q28.60% Oper. Margin- RSI (14)54.78 Volatility9.52% 24.74%
OptionableNo Debt/Eq0.01 EPS Q/Q36.10% Profit Margin- Rel Volume0.29 Prev Close2.18
ShortableYes LT Debt/Eq0.01 EarningsMay 27 BMO Payout- Avg Volume29.80M Price2.13
Recom2.00 SMA20-0.15% SMA5056.79% SMA200202.56% Volume7,365,272 Change-2.29%
Jun-20-16Initiated ROTH Capital Buy
Jan-08-16Initiated Noble Financial Buy $16
May-26-15Initiated H.C. Wainwright Buy $13
Sep-18-13Initiated Aegis Capital Buy $36
Aug-05-20 07:30AM  
Aug-03-20 10:00AM  
Jul-30-20 09:07AM  
Jul-29-20 12:05PM  
07:30AM  
Jul-27-20 06:30AM  
Jun-22-20 10:54AM  
07:30AM  
Jun-20-20 09:49AM  
Jun-18-20 07:30AM  
Jun-08-20 07:30AM  
Jun-04-20 07:30AM  
Jun-01-20 06:15AM  
May-29-20 08:00AM  
May-28-20 11:34AM  
May-27-20 08:00AM  
May-18-20 07:45AM  
May-15-20 09:30AM  
May-14-20 08:00AM  
May-11-20 08:00AM  
Apr-29-20 08:37AM  
Apr-13-20 03:27PM  
Apr-09-20 03:45PM  
12:57PM  
Apr-01-20 08:00AM  
Mar-30-20 08:30AM  
Mar-23-20 02:38PM  
09:00AM  
Mar-17-20 02:35PM  
Mar-16-20 08:00AM  
Mar-11-20 09:23AM  
Mar-09-20 10:55AM  
Mar-06-20 01:52PM  
Mar-05-20 04:45PM  
09:00AM  
Mar-04-20 03:10PM  
09:48AM  
Mar-03-20 02:41PM  
08:00AM  
08:00AM  
Feb-28-20 02:15PM  
Feb-24-20 02:59PM  
Jan-21-20 04:05PM  
Jan-16-20 09:50AM  
Jan-15-20 02:33PM  
Dec-23-19 08:39AM  
Dec-16-19 07:00AM  
Nov-29-19 05:05AM  
Nov-20-19 08:00AM  
Nov-19-19 07:56AM  
Nov-18-19 08:00AM  
Nov-15-19 08:30AM  
Nov-11-19 07:00AM  
Nov-08-19 08:14AM  
Nov-07-19 08:02AM  
Nov-05-19 08:00AM  
Oct-24-19 09:00AM  
Oct-02-19 09:23AM  
Aug-27-19 08:44AM  
Aug-26-19 12:30PM  
Aug-24-19 01:46PM  
Aug-14-19 07:00AM  
Aug-12-19 07:00AM  
Aug-07-19 11:15AM  
Jul-10-19 02:41PM  
Jul-09-19 08:00AM  
Jun-12-19 01:30PM  
Jun-03-19 06:55AM  
May-23-19 11:09AM  
May-20-19 08:30AM  
May-15-19 07:30AM  
May-06-19 07:00AM  
Apr-18-19 05:30PM  
Apr-11-19 09:30AM  
Apr-02-19 08:00AM  
Mar-28-19 07:30AM  
Mar-21-19 07:00AM  
Mar-11-19 10:40AM  
Mar-05-19 09:25AM  
Feb-28-19 05:00PM  
Feb-26-19 09:45AM  
Feb-13-19 10:03AM  
Jan-14-19 02:15PM  
08:00AM  
Jan-10-19 08:27AM  
06:30AM  
Jan-08-19 06:30AM  
Jan-04-19 07:00AM  
Dec-03-18 10:15AM  
Nov-27-18 08:38AM  
Nov-26-18 04:00PM  
06:00AM  
Nov-23-18 08:15AM  
Nov-21-18 03:21PM  
01:37PM  
08:04AM  
07:30AM  
Nov-20-18 03:10PM  
Nov-15-18 07:00AM  
Oct-22-18 07:00AM  
Heat Biologics, Inc., a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. It is developing HS-110, which is in phase II clinical trials to treat patients with advanced non-small cell lung cancer. The company's preclinical stage products include HS-130 for the treatment of advanced solid tumors; PTX-35, a humanized affinity matured monoclonal antibody, which is a functional agonist of human TNFRSF25 signaling; and PTX-45, a human TL1A-Ig fusion protein that acts as an agonist of TNFRSF25 signaling. Heat Biologics, Inc. has collaboration with Waisman Biomanufacturing to manufacture COVID-19 Vaccine. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.